About Ethris GmbHEthris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.
SNIM® RNA is a first-in-class biopharmaceutical platform for therapies of rare diseases, alternative for recombinant proteins, and for “Transcript Therapies” in regenerative medicine. ethris enabling therapies provide access to highly profitable markets.
Ethris was founded at the end of 2009 by Dr. Carsten Rudolph (CEO) and Prof. Dr. Christian Plank (CSO) and was later joined by Dr. Walter Schmidt. The goal of ethris is to rapidly and continuously translate its world-wide unique expertise into clinical trials.
CEO: Carsten Rudolph
CSO: Christian Plank
13 articles with Ethris GmbH
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases
Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA therapeutics, announced that it has raised $26.3 Million in a Series B financing round led by Laureus Capital.
Ethris Receives “Most Innovative Product Top 3” Award for COVID-19 Therapeutic Candidate at 22nd Pharma Trend Image & Innovation Award
Ethris GmbH announced that its lead COVID-19 therapeutic candidate, ETH47, has been awarded "Most Innovative Product Top 3" in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.
Data coming in about the COVID-19 pandemic shows some promising overall trends, with other more disturbing ones, particularly in breakthrough infections of the fully vaccinated.
Ethris Announces Positive Scientific Review of its mRNA-Based COVID-19 Therapeutic Program Application to Bavarian BayTherapie2020 Grant Program
Funding will advance Ethris’ development of an mRNA-based therapeutic to treat SARS-CoV-2 and its variants
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19
Neurimmune AG and Ethris GmbH announced an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of COVID-19.
Collaboration with Prof. Heymut Omran’s laboratory aimed at studying the impact of Ethris’ therapeutic mRNA strategy on primary ciliary dyskinesia
Thomas Langenickel, M.D. appointed to Chief Medical Officer as lead program ETH42 advances toward clinical trials
Change in Responsibilities Reflects Growth and Transition to Development Activities